Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,230.12
(
0.29%
)
US TECH 100
26,951.27
(
0.90%
)
Dow Jones
49,499.27
(
-0.31%
)
Brent Oil
107.80
(
-2.31%
)
Bitcoin
78,217.31
(
2.47%
)
News Focus
News Focus
Post# of 36925
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

2014shelby

Send PM Follow Ignore
Followers 72
Posts 11244
Boards Moderated 0
Alias Born 02/13/2014

2014shelby

Re: rickstereo3333 post# 35080

Saturday, 03/18/2023 1:26:04 PM

Saturday, March 18, 2023 1:26:04 PM

Post# of 36925
Interesting

Didn’t RVVTF state this in November 2022?


“The FDA has now requested additional information, which would include clinical data, for them to agree on the Study’s revised endpoints. The Company plans to go over with the FDA the overall development plan for Bucillamine in COVID-19 and further review the Pre-Dose selection data that would support the appropriate endpoints.”

Are they going to provide the FDA with what they are looking for now?
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent RVVTF News
More RVVTF News